LA Times: FDA approves knockoff of Amgen’s Neupogen chemo recovery drug

Mariah Leach, 32, a Colorado woman who uses biologics to treat rheumatoid arthritis, said she hopes pharmacies and insurers don’t force her to take a biosimilar version.

“The opportunity to have a less expensive treatment option is fabulous,” she said. “I just don’t want to be put on it without my choice. I don’t want a pharmacy to substitute a biosimilar without telling me, and without telling my doctor, so I know what I’ve been given.”  Read More